Previous studies have proven that SNHG9 acts as an oncogene for the development and progression of distinct human cancer including pancreatic 38, glioblastoma 39, non-small lung cancer (NSCLC) 37, bladder cancer 49, and prostrate 43. This evidence concerns the gene SNHG9 and non-small cell lung carcinoma.